Evaluation of ectodermal lesions in intravenous vaccinia infected mice as a method to investigate the antiviral activity of isatin beta-thiosemicarbazone derivative (TSK VI compound).
In this paper ectodermal lesions on the tails of mice inoculated intravenously with vaccinia virus were used to study the influence of N,N'-bis[methylisatin-beta-thiosemicarbazone]-2-methylpiperazine (TSKI VI) on the number and dynamics of lesion formations. The activity of this compound was compared to that of the antiviral drug, methisazone. The reduction in lesions after treatment with TSKI VI was similar to the reduction induced by methisazone, which, on the basis of earlier theroretical and experimental data as well as on the lower toxicity of TSKI VI for the tissues and a more favorable therapeutic index, makes this compound worth considering in the treatment of postvaccinal complications. This method proved very useful in examination of the substances having potential prophylactic properties in preventing generalized infections.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D008720:Methisazone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D051379:Mice; D010879:Piperazines / Q000627:therapeutic use*; D012867:Skin / Q000473:pathology; D013882:Thiosemicarbazones / Q000627:therapeutic use*; D014615:Vaccinia / Q000188:drug therapy* / Q000473:pathology
D000998:Antiviral Agents; D010879:Piperazines; D013882:Thiosemicarbazones; C023484:TSKI-VI; D008720:Methisazone